Table 1. Animal study experimental design.

Group	Formulation	rVLP Dose (μg)#	Antigen Presentation Schedule (Study Day)	Antigen Administration Route (Respective)	Sample Collection Schedule (Study Day)	Group Size (n)
1	Control	0	0, 21	IN, IN	0, 7, 14, 21, 42, 56	4
2	GI & GII Antigen	5	0, 21	IN, IN	0, 7, 14, 21, 42, 56	4
3	GI & GII Antigen	15	0, 21	IN, IN	0, 7, 14, 21, 42, 56	4
4	GI & GII Antigen	50	0, 21	IN, IN	0, 7, 14, 21, 42, 56	4
5	GI & GII Antigen	100	0, 21	IN, IN	0, 7, 14, 21, 42, 56	4
6	GI Antigen	50	0, 21	IN, IN	0, 7, 14, 21, 42, 56	4
7	GII Antigen	50	0, 21	IN, IN	0, 7, 14, 21, 42, 56	4

^#Amount of each VLP included in each dose. In Group 4, 5μg of each VLP was added for a total of 10 μg of VLPs were added in the total dose.